<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960427</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000649658</org_study_id>
    <secondary_id>WSU-2009-041</secondary_id>
    <nct_id>NCT00960427</nct_id>
  </id_info>
  <brief_title>Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery</brief_title>
  <official_title>Colorectal Cancer Stem Cells Marker Expression in Rectal Cancer Patients Undergoing Chemoradiotherapy-A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the&#xD;
      laboratory may help doctors learn more about changes that occur in DNA and identify&#xD;
      biomarkers related to cancer. It may also help doctors predict how patients respond to&#xD;
      treatment.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying biomarkers in tumor tissue and blood samples from&#xD;
      patients undergoing chemotherapy and radiation therapy for stage II or stage III rectal&#xD;
      cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To obtain the distribution of stem cell markers (CD166, CD44, and ESA) in tumor tissue&#xD;
           samples before and after neoadjuvant chemoradiotherapy (NCRT) in patients with stage II&#xD;
           or III rectal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To correlate disease-free survival after NCRT with baseline expression and change in&#xD;
           expression of stem cell markers (CD166, CD44, and ESA) after NCRT.&#xD;
&#xD;
        -  To correlate baseline and post-NCRT expression of all three stem cell markers (CD166,&#xD;
           CD44, and ESA) with circulating tumor cell (CTC) count and stem cell marker expression&#xD;
           on CTC at baseline and after NCRT.&#xD;
&#xD;
      OUTLINE: Patients receive chemotherapy according to the treating physician's choice and&#xD;
      undergo concurrent radiotherapy over approximately 6 weeks. Between 6-8 weeks after&#xD;
      completion of neoadjuvant chemoradiotherapy (NCRT), patients undergo low anterior or&#xD;
      abdominoperineal surgical resection. Some patients may then receive additional chemotherapy.&#xD;
&#xD;
      Tumor tissue samples are obtained via sigmoidoscopy-guided biopsies at baseline and at the&#xD;
      time of surgery. Blood samples are also collected at baseline and after completion of NCRT.&#xD;
      Samples are isolated for RNA analysis of CD44, CD166, and ESA expression by quantitative&#xD;
      reverse transcriptase-PCR and IHC.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years and&#xD;
      then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No surgeon available to perfrom gastroscopy&#xD;
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of stem cell markers with stated precision</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of disease-free survival with post-treatment value and change in expression of colorectal cancer stem cell markers after neoadjuvant chemoradiotherapy</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>systemic chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sigmoidoscopy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the rectum&#xD;
&#xD;
               -  Inferior margin within 16 cm of the anal verge on endoscopic exams&#xD;
&#xD;
          -  Locally advanced or low lying disease meeting 1 of the following stage criteria:&#xD;
&#xD;
               -  Stage II (T2, N0, M0) disease&#xD;
&#xD;
                    -  Distal tumor (&lt; 5 cm from anal verge) invades into muscularis propria but&#xD;
                       not beyond (T2)&#xD;
&#xD;
               -  Stage II (T3-4, N0, M0) disease&#xD;
&#xD;
                    -  Tumor invades through muscularis propria into subserosa or into&#xD;
                       non-peritonealized pericolic or perirectal tissues (T3) OR tumor directly&#xD;
                       invades other organs or structures and/or perforates visceral peritoneum&#xD;
                       (T4)&#xD;
&#xD;
               -  Stage III (any T, N1-2, M0) disease&#xD;
&#xD;
                    -  Tumor has invaded to any depth with involvement of regional lymph nodes&#xD;
                       (N1-2)&#xD;
&#xD;
          -  Resectable disease&#xD;
&#xD;
          -  No suspicious metastatic disease (M1)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  No significant co-morbidities that would preclude the use of neoadjuvant&#xD;
             chemoradiotherapy, including any of the following:&#xD;
&#xD;
               -  Severe heart failure&#xD;
&#xD;
               -  Arrhythmia&#xD;
&#xD;
               -  Significant liver or kidney dysfunction&#xD;
&#xD;
          -  No psychiatric or addictive disorder that would preclude study compliance&#xD;
&#xD;
          -  No bleeding diathesis&#xD;
&#xD;
          -  No contraindication for sigmoidoscopy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior radiotherapy or chemotherapy for rectal cancer&#xD;
&#xD;
          -  No concurrent warfarin unless appropriate bridging therapy is arranged during biopsy&#xD;
             procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhaumik B. Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>August 14, 2009</study_first_submitted>
  <study_first_submitted_qc>August 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2009</study_first_posted>
  <last_update_submitted>April 12, 2013</last_update_submitted>
  <last_update_submitted_qc>April 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

